Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
← catalyst calendarNCT06128551 · readout ≤ 865 d
Sponsored by Revolution Medicines, Inc. (industry) · RVMD — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
534estimated
Sites
55
Countries
France, Germany, Italy +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-14 | actual | When the study began enrolling |
| Primary completion | Dec 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Colorectal Cancer
- Pancreatic Ductal Adenocarcinoma
Interventions
- Drug: Elironrasib — also filed as RMC-6291
- Drug: Daraxonrasib — also filed as RMC-6236
Primary outcomes
what the primary-completion date above is the date OFNumber of patients with adverse events (AEs) in Phase 1b
measured Up to approximately 3 years
Changes in vital signs in Phase 1b
measured Up to approximately 3 years
Changes in clinical laboratory test values in Phase 1b
measured Up to approximately 3 years
Dose Limiting Toxicities in Phase 1b
measured 21 days
Changes in ECGs in Phase 1b
measured Up to approximately 3 years
Overall Response Rate (ORR) in Phase 2
measured Up to approximately 3 years
Publications
- PMID 40056080 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · RVMD's whole pipeline · Catalyst calendar · Every registered study · What changed